canceldeath

Research feed

Understand the finding first, then explore the evidence. Choose your reading level and sources independently.

Advanced research filters
Clear advanced filters

Dates show original publication, separately from when we added the story. Clinical trials lists registry activity separately. Check collection coverage.

  1. Research review· Cardiac failure review

    Meta-analysis estimates combined effect of quintuple heart failure therapy reduces cardiovascular death or HF hospitalisation

    Published Aug 17, 2026Added 1moStart a discussionShare on XSGLT2 inhibitors

    A cross-trial aggregate-data meta-analysis combined hazard ratios from six Phase III randomised trials to estimate the effect of quintuple disease-modifying therapy (including ACE inhibitors/ARBs, beta-blockers, aldosterone antagonists, SGLT2 inhibitors, and vericiguat) versus conventional therapy in heart failure with reduced ejection fraction. The imputed combined effect showed HR 0.34 (95% CI 0.27–0.42) for cardiovascular death or first heart failure hospitalisation, HR 0.31 for first HF hospitalisation alone, HR 0.47 for cardiovascular death alone, and HR 0.51 for all-cause mortality.

    Evidence assessment pending · META ANALYSIS

    Read the study · Cardiac failure review ↗